Changes in Hong Kong stocks | Jietai Technology-P (07666) rose more than 15% in early trading, leading the acceleration of AI4S commercialization in the Hong Kong stock AI pharmaceutical sector

The Zhitong Finance App learned that Jetai Technology-P (07666) rose more than 15% in early trading, leading the way for AI pharmaceutical concept stocks. As of press release, it rose 12.81% to HK$15.59, with a turnover of HK$110 million.

According to the news, the Shanghai Stock Exchange issued a notice after the market on September 4. Jietai Technology-P was officially transferred to the Hong Kong Stock Exchange's securities list. The adjustment will take effect on September 7 (Monday). This means that mainland investors can now directly trade Jietai Technology through the Shanghai-Shenzhen-Hong Kong Stock Connect, officially unlocking southbound capital. The Board believes that this inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of share transactions.

It is worth noting that in the first half of the year, the commercialization results of Jietai Technology NanoForge entered a centralized release period. Revenue for the period exceeded 154 million yuan, exceeding 47% of revenue for the full year of last year; adjusted net loss narrowed sharply by 56.4% to 51 million yuan, and R&D expenditure increased 48.1% year-on-year to 172 million yuan. During the reporting period, the company's platform capabilities expanded from designing drug delivery to systematic design of proteins, nucleic acids, delivery systems, and cellular states; the AI-driven nano-delivery platform NanoForge accelerated the commercialization process in the AI for Science (AI4S) field.